Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: A survey on behalf of Eurocord and CLWP of EBMT

Leukemia

Volumn 25, Issue 1, 2011, Pages 75-81

  Robin, M ^a   Sanz, G F ^b   Ionescu, I ^a   Rio, B ^c   Sirvent, A ^d   Renaud, M ^e   Carreras, E ^f   Milpied, N ^g,h   Mohty, M ^g,h   Beguin, Y ⁱ   Bordigoni, P ^j   De Witte, T ^k   Picardi, A ^l   Purtill, D ^a   Gluckman, E ^a   Kroger, N ^m   Rocha, V ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f HOSPITAL CLÍNIC   (Spain)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

^j CHU NANCY BRABOIS   (France)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

cord blood; myelodysplasia; transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; UNRELATED CORD BLOOD TRANSPLANTATION;

EID: 78651274309     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.219     Document Type: Article

References (40)

1. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
2. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
3. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
4. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
5. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347.
6. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-3070.
7. De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9: 1805-1811.
8. Ruutu T, Hanninen A, Jarventie G, Koistinen P, Koivunen E, Katka K et al. Intensive chemotherapy of poor prognosis myelodys-plastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 1997; 21: 133-138.
9. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99: 939-944.
10. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842-3848.
11. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009; 27: 1850-1856.
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
13. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
14. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or auto-logous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326-2331.
15. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
16. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
17. Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2006; 91: 223-230.
18. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
19. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelo-dysplastic syndromes. Blood 1997; 89: 2079-2088.
20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
21. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
22. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
23. Kaplan EM, P. Nonparametral estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Fine JG, RJ. A proportional hazard model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
25. Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
26. Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101: 4711-4713.
27. De Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-630.
28. Moreno Madureira A, Eapen M, Locatelli F, Teira P, Zhang MJ, Davies SM et al. Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation: on behalf of the European Working Group of Myelodysplastic Syndrome in Childhood, Center for International Blood and Marrow Transplant Research and Eurocord-European Group for Blood and Marrow Transplantation. Submitted.
29. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1822.
30. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256-263.
31. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113: 2410-2415.
32. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007; 110: 4543-4551.
33. Altes A, Remacha AF, Sureda A, Martino R, Briones J, Canals C et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 987-989.
34. Del Canizo MC, Martinez C, Conde E, Vallejo C, Brunet S, Sanz G et al. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant 2003; 32: 987-992.
35. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
36. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hemato-poietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846.
37. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009; 43: 839-843.
38. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585.
39. Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27: 1644-1652.
40. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110-3118.